Advisor Group’s Opus Genetics IRD Stock Holding History

Advisor Group’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$0	Hold	6	–	–	﹤0.01%	5471
2019 Q3	$0	Hold	6	–	–	﹤0.01%	5455
2019 Q2	$0	Hold	6	–	–	﹤0.01%	5381
2019 Q1	$0	Hold	6	–	–	﹤0.01%	5356
2018 Q4	$0	Hold	6	–	–	﹤0.01%	5264
2018 Q3	$0	Buy	+6	New	+$464	﹤0.01%	5245

Other funds holding IRD

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Advisor Group's IRD Position: Q4 2019 in Review

Advisor Group held its Opus Genetics (IRD) position steady in Q4 2019 at 6 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5471.

Advisor Group first reported a position in IRD in Q3 2018 and has held it in 6 quarters since. 17 funds tracked by Wall St. Rank hold IRD as of Q4 2019.

Advisor Group held 6 shares of Opus Genetics worth $0 as of Q4 2019.
Advisor Group left its Opus Genetics share count unchanged in Q4 2019.
Opus Genetics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5471 holding.
Advisor Group first reported a position in Opus Genetics in Q3 2018 and has held it in 6 quarters since.
17 funds tracked by Wall St. Rank held Opus Genetics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.